| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 753 | 301 | 517 | - |
| Cost of goods sold | 260 | 213 | 147 | - |
| General and administrative | - | - | - | 7,307 |
| Research and development | 17,273 | 22,006 | 15,418 | 22,926 |
| Selling, general and administrative | 7,610 | 7,809 | 8,136 | - |
| Total operating expenses | 25,143 | 30,028 | 23,701 | 30,233 |
| Loss from operations | -24,390 | -29,727 | -23,184 | -30,233 |
| Interest income | 590 | 832 | 662 | 911 |
| Change in fair value of contingent earnout liability | -4,893 | 5,470 | -49,731 | 8,489 |
| Change in fair value of derivatives | 4,009 | -748 | 14,930 | 1,047 |
| Interest expense | 2,612 | 2,545 | 3,000 | 2,438 |
| Total other income (expense), net | 6,880 | -7,931 | 62,323 | -8,969 |
| Net loss | -17,510 | -37,658 | 39,139 | -39,202 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.24 | 0.28 | -0.33 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.24 | 0.28 | -0.33 |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | 158,313,290 | 155,437,281 | 131,496,877 | 119,408,565 |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | 158,313,290 | 155,437,281 | 131,759,302 | 119,408,565 |
Humacyte, Inc. (HUMA)
Humacyte, Inc. (HUMA)